ELSNCT04713722
Early Life Stress and Depression: Molecular and Functional Imaging
At risk: Primary completion moved 10 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 6 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Jun 30, 2026 to Apr 30, 2027
- Eligibility criteria expanded, about 28 words
- Notable Primary and study completion dates: Apr 1, 2025 to Jun 30, 2026
- Site contact updated
- Minor Site contact updatedv7
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Mar 1, 2021 to Feb 1, 2021
- Minor Start date: Feb 1, 2021 to Mar 1, 2021v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Immuno-oxidative abnormalities
Timeframe: Baseline
Secondary (3)
Blood oxygen level dependent (BOLD) activation
Blood oxygen level dependent (BOLD) activation in emotional processing
Peripheral inflammation
Arms and interventions
MDD/childhood adversity group
subjects with current MDD who experienced childhood adversity
rMDD/ childhood adversity
subjects with a history of MDD who experienced childhood adversity
MDD
subjects in a current episode of MDD, with no history of childhood adversity
Healthy Control
healthy control subjects, with no history of childhood adversity
Sites
1 site in 1 country
- McLean HospitalBelmont, Massachusetts, United States